The first evidence-based consensus statement on tumor immunotherapy for the treatment of patients with bladder cancer was developed by the Society for Immunotherapy of Cancer (SITC) and published online by the Journal for ImmunoTherapy of Cancer, in 2017.
Immunotherapeutic drugs approved for the treatment of bladder cancer include several checkpoint inhibitors and the immunotherapeutic vaccine, Bacillus Calmette-Guérin (BCG). This consensus statement provides expert evidence-based recommendations for the use of these immunotherapies, including recommendations for patient selection, toxicity management, clinical end points and sequencing or combination of therapies.